CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab
DOI 10.1055/a-2883-7600
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJoana do Mar Ferreira Machado, Kristof Zarschler, Torsten Knieß, Martin Kreller, Matthias Miederer, Florian Brandt, Rudi Apolle, Theresa Link, Robert Winzer, Pauline Wimberger, Klaus Kopka, Oliver Kiß
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe04/2026
Jahrgang / SeitenJg. 65 · S. 265-270
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Aim [⁸⁹Zr]Zr-DFO-trastuzumab has emerged as a powerful tool to visualise non-invasively HER2 expression across metastatic lesions, complementing conventional pathological HER2 evaluation and helping to identify patients unlikely to benefit from therapy with trastuzumab-based therapies. This paper outlines the roadmap of the manufacturing implementation of [89Zr]Zr-DFO-trastuzumab at our centre in Germany. M…
Zitieren
Zitierempfehlung
Joana do Mar Ferreira Machado, Kristof Zarschler, Torsten Knieß, Martin Kreller, Matthias Miederer, Florian Brandt, Rudi Apolle, Theresa Link, Robert Winzer, Pauline Wimberger, Klaus Kopka, Oliver Kiß (2026) A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab. Nuklearmedizin - NuclearMedicine, 65 (04), 265-270. https://doi.org/10.1055/a-2883-7600
Mit CareLit weiterarbeiten